The global atopic dermatitis drug market, covering 68 countries, was valued at $10.8 billion in 2023 and is forecast to reach $26.2 billion by 2033, growing at a 9.3% CAGR. Growth is driven by the launch of seven late-stage pipeline drugs, expanded treatment options for all ages and severities, and high diagnosis and treatment rates in major markets like the US, 5EU, and Japan. The market report highlights novel therapies and mechanisms of action that will shape future competition and opportunities. This growth signals strong potential for pharmaceutical companies and investors focusing on immune disorder treatments.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
